Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:14175 |
| Name | von Hippel-Lindau disease |
| Definition | |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation benign neoplasm organ system benign neoplasm cardiovascular organ benign neoplasm hemangioma hemangioblastoma von Hippel-Lindau disease |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03401788 | Phase II | Belzutifan | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | Active, not recruiting | USA | GBR | FRA | DNK | 0 |
| NCT04924075 | Phase II | Belzutifan | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2alpha Related Genetic Alterations (MK-6482-015) | Recruiting | USA | TUR | SWE | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 7 |